NKGen Biotech
Santa Ana
About NKGen Biotech
NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. Leveraging proprietary cell expansion and activation technologies along with cutting-edge cell manufacturing expertise, NKGen Biotech has the ability to infinitely expand natural killer cells while significantly enhancing cytotoxicity.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $20.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2025)
- Ticker: nasdaq:NKGN
- Website: nkgenbiotech.com
- Phone: 949.396.6830
Industries & Categories
Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/nkgen-biotech-97358 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.